CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Nab-Paclitaxeldrug
Likely dose
Nab-Paclitaxel 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01702844
NCT01702844Phase 2Completed
CompareCT.gov

LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer

UNC Lineberger Comprehensive Cancer Center·interventional·Posted Oct 8, 2012·Updated Oct 8, 2020

In Brief

A Phase 2 clinical trial evaluating Nab-Paclitaxel for Non Small Cell Lung Cancer (NSCLC). Completed, enrolled 42 participants across 8 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer (NSCLC)
CountriesUnited States
CollaboratorsCelgene

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 8, 2012
Enrollment StartJun 25, 2013
Primary CompletionJun 23, 2017
Study CompletionJul 12, 2019
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 13.7 years ago

Interventions

Nab-Paclitaxeldrug

Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15